Zanten, J.v.; Jorritsma-Smit, A.; Westra, H.; Baanstra, M.; Bruin-Jellema, A.d.; Allersma, D.; Gareb, B.; Coppes, R.P.
Optimization of the Production Process of Clinical-Grade Human Salivary Gland Organoid-Derived Cell Therapy for the Treatment of Radiation-Induced Xerostomia in Head and Neck Cancer. Pharmaceutics 2024, 16, 435.
https://doi.org/10.3390/pharmaceutics16030435
AMA Style
Zanten Jv, Jorritsma-Smit A, Westra H, Baanstra M, Bruin-Jellema Ad, Allersma D, Gareb B, Coppes RP.
Optimization of the Production Process of Clinical-Grade Human Salivary Gland Organoid-Derived Cell Therapy for the Treatment of Radiation-Induced Xerostomia in Head and Neck Cancer. Pharmaceutics. 2024; 16(3):435.
https://doi.org/10.3390/pharmaceutics16030435
Chicago/Turabian Style
Zanten, Jacoba van, Annelies Jorritsma-Smit, Hans Westra, Mirjam Baanstra, Anne de Bruin-Jellema, Derk Allersma, Bahez Gareb, and Rob P. Coppes.
2024. "Optimization of the Production Process of Clinical-Grade Human Salivary Gland Organoid-Derived Cell Therapy for the Treatment of Radiation-Induced Xerostomia in Head and Neck Cancer" Pharmaceutics 16, no. 3: 435.
https://doi.org/10.3390/pharmaceutics16030435
APA Style
Zanten, J. v., Jorritsma-Smit, A., Westra, H., Baanstra, M., Bruin-Jellema, A. d., Allersma, D., Gareb, B., & Coppes, R. P.
(2024). Optimization of the Production Process of Clinical-Grade Human Salivary Gland Organoid-Derived Cell Therapy for the Treatment of Radiation-Induced Xerostomia in Head and Neck Cancer. Pharmaceutics, 16(3), 435.
https://doi.org/10.3390/pharmaceutics16030435
